Health News

Risk Of Kidney Disease Doubled With Use Of Fluoroquinolone Antibiotics

Date: Jun-03-2013
The risk of acute kidney disease is doubled for people taking oral fluoroquinolone antibiotics, according to a study of published in CMAJ (Canadian Medical Association Journal). Fluoroquinolones, including ciprofloxacin, levofloxacin and moxifloxacin, are common broad-spectrum antibiotics most often used to treat respiratory and urogenital infections. Case reports have indicated acute kidney injury with use, and prescription labels carry a warning of kidney failure. However, when oral fluoroquinolones are prescribed in clinical practice, kidney injury is usually not considered...

Target Meeting's 2nd World Neuroscience Online Conference Held On June 18-20, 2013: Join For Free

Date: Jun-03-2013
A Free Virtual Neuroscience Conference at Targetmeeting.com featuring 60 live presentations from academic and industry experts around the world. The 13 sessions, which will be spread over three days will discuss Cellular & Molecular Neuroscience, Neurosciences & Mathematical Model, Neurodegenerative Diseases, Traumatic Brain & Spinal Cord Injury, Neuro Sensory & Nervous System Development, Pain Management, Behavioral & Cognitive Neuroscience and many more. Attendees can earn the free Certificates of Attendance. Computer and internet connection are required...

10 Years On Tamoxifen Halves Breast Cancer Recurrence Risk

Date: Jun-03-2013
Survivors who take tamoxifen for ten years have half the risk of dying from estrogen receptor positive breast cancer, researchers from Cancer Research UK reported at the ASCO Annual Meeting in Chicago, Illinois, USA. Lead researcher, Dr Daniel Rea reported that the "aTTom" study demonstrated that estrogen receptor positive breast cancer patients who took tamoxifen for longer than five years were much less likely to suffer cancer recurrence or die from the disease. Currently, the recommended period for tamoxifen therapy is five years...

HER2 Abnormalities Found In Many Advanced Cancers

Date: Jun-03-2013
We already know that an over-active HER2 growth factor gene features in breast and gastric cancers. Now a new study reports finding mutations and other abnormalities of the gene in 14 different advanced cancers. Massimo Cristofanilli, Director of the Jefferson Breast Center at the Kimmel Cancer Center and Thomas Jefferson University Hospital, announced the study results at an oral presentation during the annual meeting of the American Society of Clinical Oncology (ASCO), which is taking place in Chicago until Tuesday...

Sorafenib (Nexavar) Delays Rare Thyroid Cancer By 5 Months

Date: Jun-03-2013
Sorafenib (Nexavar) stops metastatic thyroid cancer tumor growth for nearly twice as long as a placebo, researchers from Abramson Cancer Center and the Perelman School of Medicine at the University of Pennsylvania announced as they reported on a randomized phase III trial at the ASCO Annual Meeting in Chicago, Illinois. If the US FDA (Food and Drug Administration) approves liver and kidney cancer drug Nexavar for use in radioactive iodine-refractory differentiated thyroid cancer, it would be the first effective agent for this disease...

Fatigue And Sleep Linked To MLB Performance And Career Longevity

Date: Jun-03-2013
Two new studies show that fatigue may impair strike-zone judgment during the 162 game Major League Baseball season, and a MLB player's sleepiness can predict his longevity in the league. One study found that MLB players' strike-zone judgment was worse in September than in April in 24 of 30 teams. When averaged across all teams, strike-zone judgment was significantly worse in September compared with April. The statistical model demonstrated strong predictive value through the season...

Gender Differences Revealed For Health-Care-Associated Infections

Date: Jun-03-2013
A new study from Columbia University School of Nursing supports a growing body of evidence that women are less likely to contract bloodstream or surgical site infections than their male counterparts. Researchers investigated the incidence of infection in thousands of hospitalized patients and found the odds for women succumbing to a bloodstream infection (BSI) and surgical-site infection (SSI) were significantly lower than for men...

Approval Of The Gene Therapy Drug Glybera: The Inside Story

Date: Jun-03-2013
The scientists who led the team that developed Glybera, the first gene therapy drug approved for use in the Western world, provide a fascinating first-person account of their pioneering work in Human Gene Therapy, a peer-reviewed journal from Mary Ann Liebert, Inc., publishers. In addition, an in-depth Review reveals the inside story of the European regulatory review and approval of Glybera, chock full of twists and turn, politics, and intrigue, reviews and critiques the groundbreaking drug's path to the marketplace appears in Human Gene Therapy Clinical Development...

'Hybrid' Surveillance Strategy Aided Response To Contaminated Steroid Outbreak In Virginia

Date: Jun-03-2013
An innovative "hybrid" surveillance strategy - highlighted by close cooperation between public health officials and clinical partners - helped Virginia mount an efficient and effective response to the ongoing outbreak of fungal meningitis and other infections, according to a report in the July/August issue of Journal of Public Health Management and Practice. The journal is published by Lippincott Williams & Wilkins, a part of Wolters Kluwer Health...

Three-Year Results Show Nerve Stimulation Helps With Overactive Bladder

Date: Jun-03-2013
Beaumont Health System research finds that symptoms of overactive bladder, or OAB, were reduced in those who received tibial nerve stimulation. The three-year results published in the June issue of The Journal of Urology show participants with urinary frequency, urgency and involuntary loss of urine maintained significant improvement in their symptoms. Tibial nerve stimulation is a painless procedure that takes place in an outpatient setting. A slim needle electrode is inserted in the ankle, near the tibial nerve...